Abstract:1045 Objectives: The overall aim of this study was to validate I-131-PD-L1 SPECT tumor imaging and therapy, especially patients who has poor response to anti PD-L1 mAb therapy based on successful preparation of the probe with excellent stability. Methods: Anti-PD-L1(experimental probe) and IgG (control) were radiolabeled with iodine-131 (I-131-PD-L1, I-131-IgG) and were characterized in vitro, respectively. The stability of the probe and 4T1 cell up-taking after preparation of I-131-PD-L1 was prepared. Ability ofI-131-PD-L1 targeting to tumor was verified by bioditribution and SPECT, including blockade, I-131-IgG and I-131-PD-L1 (human). Expression of PD-L1 in tumor was tested by immunohistochemistry (IHC). To verify their therapeutic value, the study was recorded volume of tumor and their death in groups:I-131-PD-L1+ PD-L1 mAb, I-131-PD-L1, PD-L1 mAb and NS control. The side effects by I-131-PD-L1 and PD-L1 mAb were observed. Results: I-131-PD-L1 was successfully prepared and collected into EP tubes after purification by PD10 Column, with radiochemical yield (RCY): 80.21%±2.98% (n=5) and radiochemical purity (RCP): 96.51%±1.10% (n=5). The probe kept excellent stability with RCP>92% at 72 hours in vitro (n=6), RCP>90% in vivo at 24 hours and RCP>80% in vivo at 72 hours (n=3). The up-taking ratio peaked at 2 hours with 3.18%±0.86% (n=6). Ratio of T/M and T/B reached at 8.66±1.46 and 6.31±1.95 in biodistribution at 120 hours and I-131-PD-L1 in tumor was significantly suppressed (F=17.279, P=0.006) in blockade biodistribution. The breast tumor could be imaged by SPECT at 24 hours and the tumor gradually showed clearer at 48 hours and 72 hours post-injection and never be imaged in I-131-IgG (mouse), I-131-PD-L1 (blockade) and I-131-PD-L1 (human) at 72 hours. I-131-PD-L1+mAb could significantly suppress tumor growth than others groups; the median survivals of I-131-PD-L1+mAb was greatly longer than other groups, and the last one in combined therapy group survived till the 41st day which was better than mice in other groups. In the second PD-L1 mAb therapy (10 μg/g) which performed at 96 hours after the first mAb therapy (10 μg/g), we observed that 9/12 mice displayed serious adverse drug reaction of respiratory system, and died in 12 hours. Hepatorenal functions would keep normal at 7.4 MBq (200 μCi), but weight of mice dramatically descended due to poor appetite. Conclusions: I-131-PD-L1 could noninvasively monitor the expression of PD-L1 in breast tumor by SPECT scan. The probes could dramatically suppress tumor and prolong survival time. Key Words: SPECT; PD-L; Iodine-131; Theranostic probe; Molecular imaging

Experimental Study on Radioiodine Labeled Anti-PD-L1 Monoclonal Tibody As Novel Tumor Immunosuppressive Agent Imaging Probe